Drug-coated percutaneous balloon catheters

Area of Science:

• Cardiovascular medicine
• Interventional cardiology
• Biomaterials science

Background:

• Percutaneous transluminal angioplasty (PTA) revolutionized revascularization but faces challenges like elastic recoil and neointimal hyperplasia.
• Bare metal stents (BMS) mitigated recoil but not in-stent restenosis (ISR) or peripheral artery issues.
• Drug-eluting stents (DES) addressed ISR but introduced concerns of late stent thrombosis and delayed endothelialization.

Purpose of the Study:

• To explore the emergence and potential of drug-coated balloons (DCBs) as a non-stent-based revascularization strategy.
• To evaluate the efficacy of DCBs in preventing restenosis in coronary and peripheral arteries.
• To assess the role of drug delivery mechanisms in DCBs for inhibiting vascular smooth muscle cell proliferation.

Main Methods:

• Review of preliminary studies and recent clinical trials on drug-coated balloons (DCBs).
• Analysis of DCB technology involving drug delivery with nonpolymeric carrier molecules.
• Investigation of paclitaxel's role in inhibiting vascular smooth muscle cell proliferation without sustained delivery.

Main Results:

• DCBs have emerged as a rapid advancement in delivering drugs to inhibit ISR and treat de novo lesions.
• Preliminary studies indicate paclitaxel's effectiveness in inhibiting vascular smooth muscle cell proliferation, supporting DCB development.
• Recent clinical trials demonstrate DCB success in mitigating ISR in coronary and peripheral arteries, though not yet in coronary de novo lesions.

Conclusions:

• Drug-coated balloons (DCBs) represent a significant evolution in revascularization, offering a promising alternative to stenting.
• DCB technology, leveraging enhanced drug bioavailability, shows potential for treating various vascular lesions.
• While effective for ISR in coronary and peripheral arteries, further research is needed for DCB application in coronary de novo lesions.